A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
← catalyst calendarNCT06841770 · readout in 356 d
Sponsored by Lineage Cell Therapeutics, Inc. (industry) · LCTX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2027-08-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2037-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Spinal Cord Injury Cervical
- Spinal Cord Injury Thoracic
- Spinal Cord Injury, Acute
- Spinal Cord Injury
- Spinal Cord Injury, Chronic
Intervention
- Biological: OPC1
Primary outcome
what the primary-completion date above is the date OFFrequency and Severity of Adverse Events Related to the Delivery Device or Injection Procedure Through 30 Days
measured One month after LCTOPC1 injection
Permalink · LCTX's whole pipeline · Catalyst calendar · Every registered study · What changed